이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Torrent Pharmaceuticals 관리
관리 기준 확인 3/4
현재 CEO에 대한 정보가 충분하지 않습니다.
주요 정보
Samir Mehta
최고 경영자
₹260.0m
총 보상
| CEO 급여 비율 | 0.02% |
| CEO 임기 | 35.5yrs |
| CEO 소유권 | 0.0002% |
| 경영진 평균 재임 기간 | 2.5yrs |
| 이사회 평균 재임 기간 | 3.3yrs |
최근 관리 업데이트
Recent updates
Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) P/E Is On The Mark
Apr 16
Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?
Mar 03Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹22.00
Feb 05Investors Interested In Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Earnings
Jan 07Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Rather Sparingly
Nov 14Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jun 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Mar 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jul 25Torrent Pharmaceuticals' (NSE:TORNTPHARM) Soft Earnings Don't Show The Whole Picture
Jun 02Estimating The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
May 25A Look At The Intrinsic Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
Feb 18Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹25.00
Jan 27Here's Why Torrent Pharmaceuticals (NSE:TORNTPHARM) Can Manage Its Debt Responsibly
Jan 04Here's Why I Think Torrent Pharmaceuticals (NSE:TORNTPHARM) Is An Interesting Stock
Dec 14A Look At The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
Nov 07Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Sep 30Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Deserve A Spot On Your Watchlist?
Sep 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jul 02I Ran A Stock Scan For Earnings Growth And Torrent Pharmaceuticals (NSE:TORNTPHARM) Passed With Ease
Jun 01Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Shares Could Be 30% Above Their Intrinsic Value Estimate
May 14Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?
Mar 23The Torrent Pharmaceuticals (NSE:TORNTPHARM) Share Price Has Gained 84% And Shareholders Are Hoping For More
Mar 02Is It Smart To Buy Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Before It Goes Ex-Dividend?
Feb 10Do Torrent Pharmaceuticals's (NSE:TORNTPHARM) Earnings Warrant Your Attention?
Jan 19Should You Be Impressed By Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) ROE?
Dec 29Is Torrent Pharmaceuticals (NSE:TORNTPHARM) Using Too Much Debt?
Dec 08
Investors Who Bought Torrent Pharmaceuticals (NSE:TORNTPHARM) Shares Three Years Ago Are Now Up 118%
Nov 16CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2024 | ₹260m | ₹40k | ₹17b |
| Dec 31 2023 | n/a | n/a | ₹15b |
| Sep 30 2023 | n/a | n/a | ₹13b |
| Jun 30 2023 | n/a | n/a | ₹13b |
| Mar 31 2023 | ₹230m | ₹40k | ₹12b |
| Dec 31 2022 | n/a | n/a | ₹8b |
| Sep 30 2022 | n/a | n/a | ₹8b |
| Jun 30 2022 | n/a | n/a | ₹8b |
| Mar 31 2022 | ₹200m | ₹40k | ₹8b |
| Dec 31 2021 | n/a | n/a | ₹12b |
| Sep 30 2021 | n/a | n/a | ₹13b |
| Jun 30 2021 | n/a | n/a | ₹13b |
| Mar 31 2021 | ₹200m | ₹40k | ₹13b |
| Dec 31 2020 | n/a | n/a | ₹12b |
| Sep 30 2020 | n/a | n/a | ₹12b |
| Jun 30 2020 | n/a | n/a | ₹11b |
| Mar 31 2020 | ₹200m | ₹40k | ₹10b |
| Dec 31 2019 | n/a | n/a | ₹6b |
| Sep 30 2019 | n/a | n/a | ₹6b |
| Jun 30 2019 | n/a | n/a | ₹5b |
| Mar 31 2019 | ₹150m | ₹40k | ₹4b |
| Dec 31 2018 | n/a | n/a | ₹8b |
| Sep 30 2018 | n/a | n/a | ₹6b |
| Jun 30 2018 | n/a | n/a | ₹7b |
| Mar 31 2018 | ₹150m | ₹40k | ₹7b |
보상 대 시장: Samir 의 총 보상 ($USD 2.75M )은 Indian 시장( $USD 974.14K ).
보상과 수익: Samir 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Samir Mehta (60 yo)
35.5yrs
테뉴어
₹260,040,000
보상
Mr. Samir Uttamlal Mehta, B.Com., MBA serves as a Managing Director of Torrent Pharmaceuticals Limited since 1989. Mr. Mehta served as Managing Director of Torrent Power Limited. Mr. Mehta has been associa...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Executive Chairman & MD | no data | ₹260.04m | 0.00024% ₹ 2.4m | |
| Executive Director of Operations & Whole-Time Director | no data | ₹77.16m | 데이터 없음 | |
| Whole-Time Director | 1.9yrs | ₹65.88m | 0.000060% ₹ 598.7k | |
| Chief Financial Officer | 5.8yrs | ₹16.30m | 데이터 없음 | |
| Company Secretary & Compliance Officer | 1.9yrs | 데이터 없음 | 데이터 없음 | |
| Chief Customer Service Officer | 3.1yrs | 데이터 없음 | 데이터 없음 | |
| Vice President of Human Resource | no data | ₹6.56m | 데이터 없음 |
2.5yrs
평균 재임 기간
56yo
평균 연령
경험이 풍부한 관리: TORNTPHARM 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Executive Chairman & MD | 35.5yrs | ₹260.04m | 0.00024% ₹ 2.4m | |
| Executive Director of Operations & Whole-Time Director | 4.3yrs | ₹77.16m | 데이터 없음 | |
| Whole-Time Director | 1.9yrs | ₹65.88m | 0.000060% ₹ 598.7k | |
| Chairman Emeritus | 10yrs | 데이터 없음 | 0.00030% ₹ 3.0m | |
| Independent Director | less than a year | ₹2.60m | 데이터 없음 | |
| Independent Director | 2yrs | ₹4.30m | 데이터 없음 | |
| Independent Director | 5.9yrs | ₹4.90m | 0.00052% ₹ 5.2m | |
| Independent Director | 5.3yrs | ₹6.70m | 데이터 없음 | |
| Non-Executive Director | less than a year | 데이터 없음 | 데이터 없음 | |
| Independent Director | 2.2yrs | ₹6.30m | 데이터 없음 |
3.3yrs
평균 재임 기간
58yo
평균 연령
경험이 풍부한 이사회: TORNTPHARM 의 이사회는 경험(평균 재직 기간 4.3 년)으로 간주됩니다.